About Cidara Therapeutics, Inc. - Common Stock (CDTX)
Cidara Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat infectious diseases and cancer. The company is particularly known for its work in advancing its Cloudbreak platform, which aims to enhance the effectiveness of existing antifungal drugs by improving their delivery and targeting mechanisms. Cidara emphasizes the importance of addressing the growing challenge of multidrug-resistant pathogens and is actively engaged in the research and development of new treatments to combat these threats and improve patient outcomes. Through its strategic approach, Cidara strives to meet critical medical needs and contribute to the advancement of healthcare solutions. Read More
Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors who held the stock prior to today’s session are now locked in to receive a quarterly payout of $0.85 per
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts by surprise. After years of trading in the shadow of high interest rates and regulatory uncertainty, the industry
BALA CYNWYD, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
